Influence of formulation and preparation process on ambroxol hydrochloride dry powder inhalation characteristics and aerosolization properties

Drug Development and Industrial Pharmacy

Volumn 34, Issue 9, 2008, Pages 984-991

  Ren, Yachao ^a   Yu, Chaoqun ^a   Meng, Kangkang ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Aerosolization properties; Ambroxol hydrochloride; Dry powder inhalation; Leucine; Spray drying conditions

Indexed keywords

AMBROXOL; LEUCINE; MANNITOL;

AEROSOL; ARTICLE; DRUG FORMULATION; DRUG SYNTHESIS; DRY POWDER; LASER DIFFRACTION; POWDER INHALER; PROCESS OPTIMIZATION; SCANNING ELECTRON MICROSCOPY;

AEROSOLS; AMBROXOL; CHEMISTRY, PHARMACEUTICAL; MICROSCOPY, ELECTRON, SCANNING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 52149115390     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802154913     Document Type: Article

References (28)

1. Andya, J. D., Maa, Y., Costantino, H. R., Nguyen, P., Dasovich, N., Sweeney, T. D., Hsu, C. C., & Shire, S. J. (1999). The effect of formulation expients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclinal antibody. Pharm. Res., 16, 350-358.
2. Atkins, P. J. (2005). Dry powder inhalers: An overview. Respir. Care, 50, 1304-1312.
3. Bosquillon, C., Préat, V., & Vanbever, R. (2004). Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release, 96, 233-244.
4. British Pharmacopoeia Commission. (2005). Density of solids: Bulk and tapped density. In British pharmacopoeia (Vol. 4, pp. A211-A212, Appendix VQ). London: Her Majesty's Stationery Office Ltd.
5. Clarke, M. J., Peart, J., Cagnan, S., & Byron, P. R. (2002). Adhesion of powders for inhalation: An evaluation of drug detachment from surfaces following deposition from aerosol screams. Pharm. Res., 19, 322-329.
6. Codrons, V., Vanderbist, F., Ucakar, B., Préat, V., & Vanbever, R. (2004). Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci., 93, 1241-1252.
7. Corrigan, O. I. (1995). Thermal analysis of spray dried products. Thermochim. Acta, 248, 245-258.
8. Corrigan, D. O., Corrigan, O. I., & Healy, A. M. (2004). Predicting the physical state of spray dried composites: Salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems. Int. J. Pharm., 273, 171-182.
9. Corrigan, D. O., Corrigan, O. I., & Healy, A. M. (2006). Physical, chemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int. J. Pharm., 322, 22-30.
10. Dalby, R., & Suman, J. (2003). Inhalation therapy: Technological milestones in asthma treatment. Adv. Drug Deliv. Rev., 55, 779-791.
11. Disse, B. G. (1987). The pharmacology of ambroxol - review and new results. Eur. J. Respir. Dis. Suppl., 153, 255-262.
12. French, D. L., Edwards, D. A., & Niven, R. W. (1996). The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci., 27, 769-783.
13. Geuns, E. R., Toren, J. S., Barends, D. M., & Bult, A. (1997). Decrease of the stage-2 deposition in the twin impinger during storage of beclomethasone dipropionate dry powder inhalers in controlled and uncontrolled humidities. Eur. J. Pharm. Biopharm., 44, 187-194.
14. Gliński, J., Chavepeyer, G., & Platten, J. (2000). Surface properties of aqueous solutions of L-leucine. Biophys. Chem., 84, 99-103.
15. Hickey, A. J., & Concessio, N. M. (1997). Descriptors of irregular particle morphology and powder properties. Adv. Drug Deliv. Rev., 26, 29-40.
16. Ikegami, K., Kawashima, Y., Takeuchi, H., Yamamoto, H., Mimura, K., Momose, D., & Ouchi, K. (2003). A new agglomerated KSR-592 β-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo. J. Control. Release, 88, 23-33.
17. Irngartinger, M., Camuglia, V., Damm, M., Goede, J., & Frijlink, H. W. (2004). Pulmonary delivery of therapeutic peptides via dry powder inhalation: Effects of micronisation and manufacturing. Eur. J. Pharm. Biopharm., 58, 7-14.
18. Larhrb, H., Martin, G. P., Marriott, C., & Prime, D. (2003). The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int. J. Pharm., 257, 283-296.
19. Lucas, P., Anderson, K., Potter, U. J., & Staniforth, J. N. (1999). Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm. Res., 16, 1643-1647.
20. Malcolmson, R. J., & Embleton, J. K. (1998). Dry powder formulations for pulmonary delivery. Pharm. Sci. Technol. Today, 1, 394-398.
21. Najafabadi, A. R., Gilani, K., Barghi, M., & Rafiee-Tehrani, M. (2004). The effect of vehicle on physical properties and aerosolization behavior of disodium cromoglycate microparticles spray dried alone or with L-leucine. Int. J. Pharm., 285, 97-108.
22. Okamoto, H., Aoki, M., & Danjo, K. (2000). A novel apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration. J. Pharm. Sci., 89, 1028-1035.
23. Seifart, C., Clostermann, U., Seifart, U., Mqller, B., Vogelmeier, C., VonWichert, P., & Fehrenbach, H. (2005). Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol. Appl. Pharmacol., 203, 27-35.
24. Shekunov, B. Y., Feeley, J. C., Chow, A. H. L., Tong, H. H. Y., & York, P. (2003). Aerosolization behaviour of micronised and supercritically- processed powders. J. Aerosol. Sci., 34, 553-568.
25. Surendrakumar, K., Martyn, G. P., Hodgers, E. C. M., Jansen, M., & Blair, J. A. (2003). Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release, 91, 385-394.
26. Timsina, M. P., Martin, G. P., Marriott, C., Ganderton, D., & Yianneskis, M. (1994). Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm., 101, 1-13.
27. Von, R. K. (1978). Ergebnisse einer klinischen prüfung mit ambroxol zur frage der postoperativen bronchitisbehandlung. Arzneim. Forsch., 28, 934-935.
28. Zeng, X. M., Martin, G. P., Marriott, C., & Pritchard, J. (2000). The influence of carrier morphology on drug delivery by dry powder inhalers. Int. J. Pharm., 200, 93-106.